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Abstract
While Pakistan has made progress toward achieving Millennium Development Goal 5 for maternal health, it is
unlikely to achieve the target; further, it is also not on track for Millennium Development Goal 4 regarding child
health. Two low-cost, temperature stable and life-saving drugs, misoprostol and chlorhexidine, can respectively
avert maternal and newborn deaths, and are particularly pertinent for poor and marginalized areas which bear the
brunt of maternal and newborn deaths in Pakistan. In response, Mercy Corps led focused advocacy efforts to promote
changes in policies, protocols, and regulatory environments for misoprostol (2012–2014) and for chlorhexidine (2014).
These short-duration advocacy projects facilitated significant policy gains, such as inclusion of misoprostol and
chlorhexidine into province-specific essential drug lists, development and endorsement of clinical protocols for
the two drugs by provincial health departments, inclusion of misoprostol into pre-service training curriculum
for several health cadres, and application for registration of chlorhexidine (at the concentration required for
newborn care) by two pharmaceutical companies. These results were achieved by a consultative and evidence-based
process which generated feedback from community members, program implementers, and policymakers, and ultimately
put the government in the driver’s seat to facilitate change. Community Action Dialogue forums were linked with
provincial-level Technical Working Groups and Provincial Steering Committees, who passed on endorsed
recommendations to the Health Secretary. The key factors which facilitated change were the identification of
champions within the provincial health departments, prioritization of relationship building and follow-up,
focus on concrete advocacy aims rather than broad objectives, and the use of multi-stakeholder forums to
secure an enabling environment for the policy changes to take root. While these advocacy initiatives resulted
in significant policy changes in Pakistan’s devolved health system, to ensure these policy changes have an
impact on health outcomes, Pakistan should focus on the scale-up of appropriate use of chlorhexidine and
misoprostol. Further, future policy initiatives in Pakistan should make use of similar multi-stakeholder policy
forums, while ensuring a third party to facilitate the process so that civil society and community voices are
not lost in the policy development discussion.
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Background
While Pakistan has made progress toward achieving Mil-
lennium Development Goal 5 for maternal health, it is
unlikely to achieve the stipulated target; further, it is also
not on track to achieve Millennium Development Goal 4
regarding child health. With a maternal mortality of 170
per 100,000 live births, Pakistan is among the 10 countries
contributing 58% of all maternal deaths reported in 2013
[1]. Poor maternal health outcomes are directly linked to
poor child health outcomes, particularly for infants (i.e.
under age 1) and newborns (i.e. 28 days or younger).
Pakistan has the third highest number of newborn deaths
in the world (194,000 in 2010) [2].
The leading cause of maternal deaths (27%) in
Pakistan is postpartum haemorrhage (PPH) [3], a condi-
tion which is easily preventable or treatable through
proper use of uterotonic drugs (drugs which contract
the uterus to reduce bleeding). Ideally, PPH should be
prevented/treated through the participation of skilled
birth attendants (SBA) who can administer oxytocin
through a reliable cold chain. However, only 52% of
births in Pakistan are attended by a SBA, only a portion
of which have access to a reliable cold chain [4]. In the
absence of a reliable cold chain and until SBAs are
widely accessible, misoprostol (a temperature-tolerant
drug in tablet form) can make significant contributions
toward reducing maternal mortality by preventing and
treating PPH [5–9].
Nearly two-thirds of all child deaths in Pakistan occur
during the newborn period, with 74% of newborn deaths
taking place during the first week of life [4]. Thus, im-
proving access to lifesaving drugs and skills immediately
following birth and the days after is critical to averting
newborn deaths. Worldwide, up to 30% of newborn
deaths are attributable to sepsis, a condition which could
be prevented through proper umbilical cord care [10].
Chlorhexidine (specifically 7.1% chlorhexidine digluconate
delivering 4% active chlorhexidine) is a temperature-
tolerant low-cost drug which can reduce newborn mortal-
ity rates by up to 23% [11]. It can be administered to the
umbilical stump to prevent sepsis by any health care pro-
vider or even family members.
These two low-cost, temperature-stable, and life-saving
drugs, misoprostol and chlorhexidine, are particularly per-
tinent for poor and marginalized areas, which bear the
brunt of maternal and newborn deaths in Pakistan.
Mercy Corps Pakistan response
In response to the challenges facing maternal and newborn
survival, Mercy Corps led focused advocacy efforts with the
goal of promoting changes in policies, protocols, and regu-
latory environments for misoprostol between 2012 and
2014 and for chlorhexidine in 2014. At the time of the ini-
tiatives, misoprostol was widely available but underutilized
for the purpose of PPH prevention and treatment. Chlor-
hexidine, at the concentration required for newborn cord
care, was not locally produced nor available in the market.
Both advocacy initiatives targeted the provincial depart-
ments of health. After the devolution of the federal health
system in 2011, the departments have been responsible for
the development and implementation of health pol-
icies within their province/region. Misoprostol advocacy
work took place in two provinces (Balochistan and Khyber
Pakhtunkhwa) and two regions (Azad Jammu Kashmir and
the Federally Administered Tribal Areas). Chlorhexidine
advocacy work targeted three provinces (Balochistan,
Punjab, and Sindh) and two regions (Azad Jammu
Kashmir and Gilget-Baltistan). It should be noted that
Balochistan has some of the poorest health outcomes
in Pakistan, for example, with an estimated maternal
mortality of 785 per 100,000 live births [3].
Policy gains
The advocacy projects were of short duration, lasting 1–2
years, and facilitated significant policy gains. In summary,
misoprostol was included in province-specific essential
drug lists; clinical protocols for appropriate use of miso-
prostol in community and facility settings were developed
and endorsed by provincial health departments; and the
pre-service training curriculum was revised to include mi-
soprostol for key health cadres including nurses and Lady
Health Visitors (facility based), Lady Health Workers
(LHWs; community based), and Community Midwives
(community based). With regards to chlorhexidine, clin-
ical guidelines for multiple application of chlorhexidine
until 7 days immediately after birth or until the cord
stump separates were approved by provincial health de-
partments; it was included in provincial essential drug lists
and purchase lists of the Executive District Officer Health
(government’s lead representative for the health system at
the district level); it was included in Community Midwives
birthing kits and LHW service lists; and two pharmaceut-
ical companies (MediSearch and ZAFA) applied for the
registration of 7.1% chlorhexidine digluconate delivering
4% active chlorhexidine to the Drug Regulatory Authority.
Advocacy pathways
To achieve these results, Mercy Corps worked in part-
nership with the provincial departments of health and
other key stakeholders (for example, the misoprostol ad-
vocacy initiative was implemented in partnership with
Khwendo Kor, a local NGO). A consultative process which
put the government in the driver’s seat was facilitated to
determine which policy changes to make. The consultative
strategy aimed to contextualize global best practices for
misoprostol and chlorhexidine for Pakistan, on the basis of
feedback and inputs from community members, program
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implementers, and policymakers. Mercy Corps followed a
three-step process to achieve its policy aims.
Consolidation of evidence
In both initiatives, Mercy Corps first commissioned a
desk review to look at the global, regional, and local evi-
dence available for the particular drug. This was followed
by field consultations in the form of key informant inter-
views and focus group discussions to understand percep-
tions, availability, and use of the drugs. The desk review
and field consultations were combined into a situational
analysis which was widely disseminated to all stakeholders.
Presentation of evidence
To facilitate a multi-stakeholder process which ensured
that community voices were reflected in policy discus-
sion, Mercy Corps supported three tiers of forums. First,
Community Advocacy Dialogue Forums engaged local
NGOs, key influencers, community and district repre-
sentatives, and stakeholders. Feedback was gained on
strategies to influence provincial level policy. The partic-
ipant’s commitment to implementing policies was also
endorsed. The feedback from the Community Advocacy
Dialogue Forums was shared with provincial level Tech-
nical Working Groups (TWG), which reviewed the evi-
dence (e.g. from the situational analysis) and the feedback.
Recommendations were provided by the TWGs to the
Provincial Steering Committees (PSCs) on the specific pol-
icies necessary to endorse. The PSCs were chaired by the
Deputy General Health Services who passed on endorsed
recommendations to the Health Secretary. The target au-
diences for the advocacy efforts therefore included (1) pol-
icymakers at the provincial level, including but not limited
to women parliamentarians, the Minister for Health, the
Health Secretary, the Director General for Health Services,
and provincial Programme Managers for the Provincial
Programme for Family Planning and Primary Health Care
and the Provincial Programme for Maternal, Newborn and
Child Health (MNCH), which included representatives
of the Society of Obstetricians and Gynaecologists of
Pakistan, the Pakistan Nursing Council, the Pakistan
Medical Association, and the Pakistan Paediatric As-
sociation; (2) policy implementers at the district level, in-
cluding but not limited to the Executive District Officer
(Health), District Coordinators for LHWs and MNCH pro-
grammes, public and private healthcare providers, owners
of private pharmacies/drug stores, and obstetricians and
gynaecologists; and (3) opinion leaders/champions, includ-
ing but not limited to locally elected parliamentarians/
politicians, civil society and community-based organiza-
tions, journalists, religious leaders, tribal chiefs, LHWs and
other community health workers such as traditional birth
attendants, and women of reproductive age.
Consensus building
Through these tiers of multi-stakeholder forums com-
bined with one-on-one advocacy meetings, Mercy Corps
facilitated a process whereby the government, in consult-
ation with the leading organizations and individuals in
MNCH at the provincial level, came to their own con-
clusions about which policies should be endorsed. Mercy
Corps positioned itself as a facilitator, not the leader, to
ensure the conclusions were truly driven by the govern-
ment and thus sustainable after the advocacy initiatives
came to a close.
What facilitated change?
There were several key factors which facilitated change.
First, Mercy Corps identified champions within the pro-
vincial departments of health to spearhead the advocacy
efforts from within the government. Second, Mercy Corps
emphasized relationship building and follow-up which
consumed the majority of the time that staff dedicated to
this project. Third, the initiatives’ focus on specific, con-
crete advocacy aims, rather than broad objectives, helped
the committees to target their efforts and create change in
a particular area. Finally, and perhaps most importantly,
multi-stakeholder forums, which brought together influen-
tial players from all backgrounds, was paramount to secur-
ing an enabling environment for the policy changes to be
proposed and eventually take root.
Conclusion
While these advocacy initiatives resulted in significant
policy changes in Pakistan’s devolved health system, the
changes will only have an impact on MNCH outcomes if
they are implemented in a timely way with sufficient
support and oversight to ensure quality of service deliv-
ery. Thus, the battle is only half-won and the attention
of the MNCH community in Pakistan should focus on
the scale-up of appropriate use of chlorhexidine and mi-
soprostol, in addition to the multiple other priorities in
the sector. Further, several of the provincial departments
of health have constituted TWGs and PSCs within the
government; future policy initiatives in Pakistan should
make use of these forums. It remains critical for a third
party to facilitate the process to ensure civil society and
community voices are not lost in the policy development
discussion.
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